Friday, June 29, 2018

Lenabasum shows promise for diffuse cutaneous systemic sclerosis

The selective cannabinoid receptor type 2 agonist lenabasum exhibited an acceptable safety profile while improving outcomes in patients with diffuse cutaneous systemic sclerosis, according to results of a phase II study.

No comments:

Post a Comment

Forgetfulness a strong barrier to treatment adherence in lupus, vasculitis patients

While self-reported adherence to treatment appears to be high for both systemic lupus erythematosus and vasculitis, patient forgetfulness re...